Department of Woman and Child, Division Woman, Fetal Medicine Unit, University Hospital Gasthuisberg Leuven, Leuven, Belgium.
Prenat Diagn. 2011 Jul;31(7):678-88. doi: 10.1002/pd.2781. Epub 2011 Jun 8.
Sacrococcygeal teratoma (SCT) is one of the most common tumors in newborns with a birth prevalence of up to 1 in 21,700 births. Routine fetal anomaly screening programs allow for prenatal diagnosis in many cases. Fetal ultrasound with Doppler evaluation and more recently magnetic resonance imaging may be used to document the extent of the tumor as well as identifying the population at risk for serious fetal complications. Rapidly growing SCT and highly vascularized tumors are more likely to have hemodynamic repercussions. Fetal hydrops is usually considered as a poor prognostic marker and a potential indicator for fetal intervention. Newborns with SCT require stabilization prior to early surgical resection. In case of malignancy additional chemotherapy may be required. SCT may result in significant morbidity, either directly or as a consequence of surgical therapy. Careful postnatal follow-up is required for timely identification and treatment of complications as well as recurrence. This paper aims to review the perinatal management of this condition.
骶尾部畸胎瘤（SCT）是新生儿中最常见的肿瘤之一，发病率高达每 21700 例出生一例。常规的胎儿异常筛查计划可在许多情况下进行产前诊断。胎儿超声检查结合多普勒评估，以及最近的磁共振成像，可用于记录肿瘤的范围，并确定有严重胎儿并发症风险的人群。快速生长和高度血管化的 SCT 更有可能产生血液动力学影响。胎儿水肿通常被认为是预后不良的标志物，也是胎儿干预的潜在指标。患有 SCT 的新生儿在进行早期手术切除前需要稳定病情。如果是恶性肿瘤，可能需要额外的化疗。SCT 可能会导致严重的发病率，无论是直接的还是手术治疗的结果。需要进行仔细的产后随访，以及时发现和治疗并发症以及复发。本文旨在回顾该疾病的围产期管理。
